ReviewJournal of mood and anxiety disorders2023
Trial-Based Cognitive Therapy for depressive and anxious symptoms: A systematic review and meta-analysis of efficacy and dropout rates.
Review in Journal of mood and anxiety disorders, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: With depression and anxiety disorders increasing globally, effective therapies like Trial-Based Cognitive Therapy (TBCT), a novel Cognitive-Behavioral Therapy (CBT) variant, are crucial. This systematic review and meta-analysis aim to assess TBCT's efficacy in reducing depression and anxiety symptoms and its dropout rates compared with other psychotherapies. Methods: Comprehensive searches across databases like CENTRAL, PUBMED/MEDLINE, PsycINFO, LILACS/BVS, Clinicaltrials.gov, WHO International Clinical Trials Registry Platform, and Google Scholar were conducted. Eligibility was determined based on the trial's ability to potentially benefit from TBCT and measures of depression or anxiety symptoms using validated scales. Ten RCTs involving 1245 participants were included. The meta-analysis considered post-treatment assessments, dropout rates, and risk of bias. This study was registered on PROSPERO (CRD42021252907). Results: We identified 10 RCTs involving 1245 participants with various conditions, including Social Anxiety Disorder, Major Depressive Disorder, Post-Traumatic Stress Disorder, and Obsessive-Compulsive Disorder. The meta-analysis of 5 RCTs found no significant difference in symptom reduction between TBCT and other first-choice psychotherapies. TBCT's dropout rates were comparable to other psychotherapies. The majority of RCTs had a low risk of bias. Conclusions: TBCT shows comparable efficacy to other psychotherapies in both short-term symptom reduction and long-term treatment gains across various mental health conditions. Its flexibility across different settings and conditions supports its utility in diverse therapeutic contexts. Despite these promising results, more rigorous and geographically diverse studies are necessary to confirm these findings. TBCT offers a promising alternative approach in the psychotherapeutic intervention landscape for mental health disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.